Johnson & Johnson (J&J) can now offer rheumatoid arthritis (RA) patients in the US an alternative to its subcutaneous version of Simponi after regulators approved the intravenous version Simponi Aria.

The CHMP positive opinion was based on the findings from the GO-AHEAD study, which demonstrated significant clinical improvement in patients with active nr-axial SpA treated with golimumab, compared ...

Johnson & Johnson's Simponi gains FDA approval for treating pediatric ulcerative colitis, expanding options for young patients with this chronic condition. “Ulcerative colitis is a complex, lifelong ...

Cost regulators for therapies funded by the NHS in England and Wales have added MSD’s Simponi (golimumab) to the list of treatments recommended for severe non-radiographic axial spondyloarthritis.

If you have a certain kind of autoimmune condition, your doctor might suggest Simponi or Simponi Aria as a treatment option for you. The active ingredient in Simponi and Simponi Aria is golimumab. An ...

Johnson & Johnson JNJ announced that the FDA has granted approval to its TNF inhibitor, Simponi Aria for the treatment of children 2 years and older with active polyarticular course juvenile ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Simponi Aria for the treatment of polyarticular juvenile idiopathic arthritis in patients ...

Johnson & Johnson JNJ announced that the FDA has granted approval to its TNF inhibitor, Simponi Aria for the treatment of children 2 years and older with active polyarticular course juvenile ...

Janssen Biotech and Janssen Biologics are requesting Food and Drug Administration and European Medicines Agency approval to make their Simponi drug a treatment for "adult patients with moderately to ...